CG Oncology (CGON) Accumulated Expenses (2023 - 2026)

CG Oncology (CGON) has 4 years of Accumulated Expenses data on file, last reported at $25.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 65.52% year-over-year to $25.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.9 million (up 65.52% YoY), and the FY2025 full-year result was $24.2 million, up 65.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $25.9 million, up from $24.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $25.9 million in Q1 2026 and bottomed at $5.1 million in Q1 2024.
• The 4-year median for Accumulated Expenses is $15.2 million (2024), against an average of $15.8 million.
• The widest annual swing landed in 2024, when Accumulated Expenses surged 40.43%; it then jumped 222.36% in 2025.
• A 4-year view of Accumulated Expenses shows it stood at $10.4 million in 2023, then soared by 40.43% to $14.7 million in 2024, then surged by 65.07% to $24.2 million in 2025, then climbed by 7.05% to $25.9 million in 2026.
• The last three Accumulated Expenses figures came in at $25.9 million (Q1 2026), $24.2 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.

Peer Comparison